Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 384 citing Boland: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia,.... (0.10 sec) 

Type 1 diabetes: new perspectives on disease pathogenesis and treatment


MA Atkinson, GS Eisenbarth - The Lancet, 2001 - Elsevier
As our knowledge of type 1 (insulin-dependent) diabetes increases, so does our appreciation
for the pathogenic complexity of this disease and the challenges associated with its
treatment. Many new concepts about the pathogenesis of this disorder have arisen. The ...
Cited by 568 - Related articles - BL Direct - All 15 versions

Insulin pump therapy

- angrylapdog.com
J Weissberg-Benchell, J Antisdel- … - Diabetes …, 2003 - care.diabetesjournals.org.p. …
RESEARCH DESIGN AND METHODS—Studies were identified and data regarding study
design, year of publication, sample size, patient's age, diabetes duration, and duration of CSII
therapy were collected. Means and SDs for glycohemoglobin, blood glucose, insulin ...
Cited by 295 - Related articles - BL Direct - All 14 versions

Glycaemic control with continuous subcutaneous insulin infusion compared with …

- bmj.com
J Pickup, M Mattock, S Kerry - British Medical Journal, 2002 - bmj.com
Continuous subcutaneous insulin infusion, often called insulin pump therapy, was introduced
in the 1970s as a way of achieving and maintaining strict control of blood glucose concentrations
in people with type 1 (insulin dependent) diabetes. 1 Short acting insulin is infused ...
Cited by 257 - Related articles - BL Direct - All 10 versions

Continuous subcutaneous insulin infusion at 25 years


J Pickup, H Keen - Diabetes care, 2002 - Am Diabetes Assoc
Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic subjects
to achieve strict blood glucose control. A quarter of a century after its introduction, world-wide
use of CSII is increasing. We review the evidence base that justifies this increase, ...
Cited by 225 - Related articles - BL Direct - All 8 versions

Continuous subcutaneous insulin infusion: a comprehensive review of insulin …


MJ Lenhard, GD Reeves - Archives of Internal Medicine, 2001 - Am Med Assoc
A tremendous amount of data suggest that near-normal glycemic control prevents or delays complications
of diabetes, which has led to a dramatic increase in continuous subcutaneous insulin infusion
(CSII) or insulin pump use. In this article, the data supporting CSII in type 1 diabetes is ...
Cited by 191 - Related articles - BL Direct - All 5 versions

Safety and effectiveness of insulin pump therapy in children and adolescents with …

- diabetesjournals.org
LP Plotnick, LM Clark, FL Brancati, T Erlinger - Diabetes Care, 2003 - Am Diabetes Assoc
RESULTS—There was a small but significant decrease in HbA 1c at 3–6 months after pump
start (7.7 vs. 7.5%; P = 0.03). HbA 1c levels then gradually increased and remained elevated
after 1 year of follow-up; however, this association was confounded by age and diabetes ...
Cited by 146 - Related articles - BL Direct - All 10 versions

Continuous subcutaneous insulin infusion therapy for children and adolescents: an …


AK Maniatis, GJ Klingensmith, RH Slover, CJ Mowry, … - Pediatrics, 2001 - Am Acad Pediatrics
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add to Reddit
Add to Technorati Add to Twitter What's this? ... From the Barbara Davis Center for Childhood
Diabetes, University of Colorado Health Sciences Center, Denver, Colorado.
Cited by 143 - Related articles - All 5 versions

Comparison of continuous subcutaneous insulin infusion and multiple daily …

- input.me.uk [PDF] 
N Weintrob, H Benzaquen, A Galatzer, S Shalitin, L … - Pediatrics, 2003 - Am Acad Pediatrics
Results. The changes in HbA 1c and fructoseamine values were similar in the 2 arms over
time. At the end of the study, mean HbA 1c level measured 8.05 ± 0.78%. There were no differences
between the treatment modes in frequency of symptomatic hypoglycemic or ...
Cited by 135 - Related articles - BL Direct - All 7 versions

Psychosocial therapies in diabetes


AM Delamater, AM Jacobson, B Anderson, D Cox, … - Diabetes Care, 2001 - Am Diabetes Assoc
This study presents the summary and recommendations of the Psychosocial Therapies Working
Group, originally presented at the conference on Behavioral Science Research in Diabetes,
held in November 1999, at the National Institutes of Health. In this study, we first highlight ...
Cited by 128 - Related articles - BL Direct - All 6 versions

A two-center randomized controlled feasibility trial of insulin pump therapy in young …


DM Wilson, BA Buckingham, EL … - Diabetes …, 2005 - care.diabetesjournals.org.p. …
RESULTS—The 19 subjects' ages ranged from 1.7 to 6.1 (mean 3.6) years, duration of diabetes
ranged from 0.6 to 2.6 (mean 1.4) years, and baseline HbA 1c ranged from 6.7 to 9.6% (mean
7.9%). Seven subjects were male. Nine subjects were randomized to start CSII and 10 to ...
Cited by 109 - Related articles - All 7 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google